×
About 5,339 results

ALLMedicine™ Hyperkalemia Center

Research & Reviews  2,179 results

Pathophysiology and Treatment of Malignant Hyperthermia.
https://doi.org/10.1097/TME.0000000000000344
Advanced Emergency Nursing Journal; Gregory H, Weant KA

Apr 29th, 2021 - Malignant hyperthermia (MH) is caused by a genetic disorder of the skeletal muscle that induces a hypermetabolic response when patients are exposed to a triggering agent such as volatile inhaled anesthetics or depolarizing neuromuscular blockers. ...

Hyperkalemia in a Patient With Leukemia.
https://doi.org/10.1053/j.ajkd.2020.08.020
American Journal of Kidney Diseases : the Official Journa... Su YJ, Huang CC et. al.

Apr 25th, 2021 - Hyperkalemia in a Patient With Leukemia.|2021|Su YJ,Huang CC,Hsieh CY,Hung YS,Chan MJ,|

Trimethoprim-Sulfamethoxazole and Hyperkalemia.
https://www.ncbi.nlm.nih.gov/pubmed/33886248
Nephrology Nursing Journal : Journal of the American Neph... Smith CA

Apr 22nd, 2021 - Trimethoprim-Sulfamethoxazole and Hyperkalemia.|2021|Smith CA,|

Hyperkalemia: The Trojan horse of pediatric transfusion?
https://doi.org/10.1111/trf.16353
Transfusion Romon I, Cortes MA

Apr 8th, 2021 - Hyperkalemia: The Trojan horse of pediatric transfusion?|2021|Romon I,Cortes MA,|

see more →

Drugs  175 results see all →

Clinicaltrials.gov  2,635 results

Pathophysiology and Treatment of Malignant Hyperthermia.
https://doi.org/10.1097/TME.0000000000000344
Advanced Emergency Nursing Journal; Gregory H, Weant KA

Apr 29th, 2021 - Malignant hyperthermia (MH) is caused by a genetic disorder of the skeletal muscle that induces a hypermetabolic response when patients are exposed to a triggering agent such as volatile inhaled anesthetics or depolarizing neuromuscular blockers. ...

Hyperkalemia in a Patient With Leukemia.
https://doi.org/10.1053/j.ajkd.2020.08.020
American Journal of Kidney Diseases : the Official Journa... Su YJ, Huang CC et. al.

Apr 25th, 2021 - Hyperkalemia in a Patient With Leukemia.|2021|Su YJ,Huang CC,Hsieh CY,Hung YS,Chan MJ,|

Trimethoprim-Sulfamethoxazole and Hyperkalemia.
https://www.ncbi.nlm.nih.gov/pubmed/33886248
Nephrology Nursing Journal : Journal of the American Neph... Smith CA

Apr 22nd, 2021 - Trimethoprim-Sulfamethoxazole and Hyperkalemia.|2021|Smith CA,|

Hydrochlorothiazide - hydrochlorothiazide capsule-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39d4dbd3-8f24-4898-a240-e94e06fa229a

Apr 13th, 2021 - Hydrochlorothiazide capsules are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, hydrochlorothiazide capsules...

see more →

News  349 results

Fast Five Quiz: Hyperkalemia Management
https://reference.medscape.com/viewarticle/948621

Apr 8th, 2021 - Hyperkalemia is a clinically important acute electrolyte abnormality that can result in significant morbidity and life-threatening cardiac arrhythmias. Although uncommon in the general population, hyperkalemia is much more prevalent in patients wi...

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.staging.medscape.com/viewarticle/940012

Oct 28th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.medscape.com/viewarticle/940012

Oct 28th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Novel Drug Slows Progression of Diabetic Kidney Disease
https://www.staging.medscape.com/viewarticle/939724

Oct 22nd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

Novel Drug Slows Progression of Diabetic Kidney Disease
https://www.medscape.com/viewarticle/939724

Oct 22nd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

see more →

Patient Education  1 results see all →